Therefore, therapeutic targeting of JAK/STAT signaling has to be expanded on various levels, including the development of novel STAT3/5 inhibitors and the extension of pre-clinical and clinical studies to large cohorts of T-PLL and other T-cell lymphomas, all with well-characterized tumor material (e.g., JAK/STAT activation state). The gene discussed is STAT3; the disease is T-cell non-Hodgkin lymphoma.